Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index

References

• Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(Suppl 90231):I9–16. doi:10.1161/01.CIR.0000078469.07362.E6
   Web of Science ®Google Scholar
• Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–4847. doi:10.1200/JCO.2009.22.3271
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722. doi:10.1001/jama.293.6.715
   PubMed Web of Science ®Google Scholar
• Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis. Thromb Haemost. 2018;118(2):251–265. doi:10.1160/TH17-08-0596
   PubMed Web of Science ®Google Scholar
• Connolly GC, Francis CW. Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2013;2013:684–691. doi:10.1182/asheducation-2013.1.684
   PubMed Web of Science ®Google Scholar
• Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10(10):380. doi:10.3390/cancers10100380
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi:10.1200/JCO.19.01461
   PubMed Web of Science ®Google Scholar
• Ihadaddene R, Carrier M. Thromboprophylaxis for medical patients with cancer: what do the guidelines say? Clin Pract. 2014;11(2):155–168. doi:10.2217/cpr.14.2
   Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al.; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656. doi:10.1200/JCO.2014.59.7351
   PubMed Web of Science ®Google Scholar
• Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780–785. doi:10.1002/ajh.25494
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019;3(22):3770–3779. doi:10.1182/bloodadvances.2019000369
   PubMed Web of Science ®Google Scholar
• Shin S, Noh Y. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. Ther Clin Risk Manag. 2018;14:833–847. doi:10.2147/TCRM.S148840
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al.; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719. doi:10.1056/NEJMoa1814468
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al.; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728. doi:10.1056/NEJMoa1814630
   PubMed Web of Science ®Google Scholar
• Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015;16(1):11–17. doi:10.5811/westjem.2014.12.22933
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907. doi:10.1182/blood-2007-10-116327
   PubMed Web of Science ®Google Scholar
• Debbie Jiang MD, Alfred Ian Lee MD. Thrombotic risk from chemotherapy and other cancer therapies. Cancer Treat Res. 2019;179:87–101. doi:10.1007/978-3-030-20315-3_6
   Google Scholar
• Choi YJ, Kim DJ, Shin S. Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus. Cancer Manag Res. 2019;11:7427–7438. doi:10.2147/CMAR.S215107
   PubMed Web of Science ®Google Scholar
• Mulder FI, Candeloro M, Kamphuisen PW, et al.; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277–1287. doi:10.3324/haematol.2018.209114
   PubMed Web of Science ®Google Scholar
• Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011;9(Suppl 1):316–324. doi:10.1111/j.1538-7836.2011.04346.x
   PubMed Web of Science ®Google Scholar
• Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529–535. doi:10.1111/j.1538-7836.2006.01804.x
   PubMed Web of Science ®Google Scholar
• Rak J, Milsom C, Magnus N, Yu J. Tissue factor in tumour progression. Best Pract Res Clin Haematol. 2009;22(1):71–83. doi:10.1016/j.beha.2008.12.008
   Web of Science ®Google Scholar
• Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep. 2013;33(5):e00064. doi:10.1042/BSR20130057
   PubMed Web of Science ®Google Scholar
• Han X, Guo B, Li Y, Zhu B. Tissue factor in tumor microenvironment: a systematic review. J Hematol Oncol. 2014;7:54. doi:10.1186/s13045-014-0054-8
   PubMed Web of Science ®Google Scholar
• Smith AW, Reeve BB, Bellizzi KM, et al. Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev. 2008;29(4):41–56.
   Google Scholar
• Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–655. doi:10.1002/cncr.27772
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–593. doi:10.1001/archinte.158.6.585
   PubMed Web of Science ®Google Scholar
• White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(Suppl 3):S7–15. doi:10.1016/j.amepre.2013.10.029
   Web of Science ®Google Scholar
• Roy S, Vallepu S, Barrios C, Hunter K. Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer. J Clin Med Res. 2018;10(12):911–919. doi:10.14740/jocmr3617w
   PubMedGoogle Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346. doi:10.1002/cncr.23062
   PubMed Web of Science ®Google Scholar
• Noh Y, Jeon SM, Shin S. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy. Int J Cancer. 2019;144(7):1530–1539. doi:10.1002/ijc.31870
   Web of Science ®Google Scholar
• Iorga RA, Bratu OG, Marcu RD, et al. Venous thromboembolism in cancer patients: still looking for answers. Exp Ther Med. 2019;18(6):5026–5032. doi:10.3892/etm.2019.8019
   Web of Science ®Google Scholar
• Aikens GB, Osmundson JR, Rivey MP. New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop. 2014;5(3):188–203. doi:10.5312/wjo.v5.i3.188
   Google Scholar
• Song AB, Rosovsky RP, Connors JM, Al-Samkari H. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. Vasc Health Risk Manag. 2019;15:175–186. doi:10.2147/VHRM.S132556
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Connors JM. The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers (Basel). 2018;10(8):271. doi:10.3390/cancers10080271
   Web of Science ®Google Scholar
• Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007;22(7):997–1002. doi:10.1007/s11606-007-0228-y
   Web of Science ®Google Scholar
• Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(Suppl 90231):I17–21. doi:10.1161/01.CIR.0000078466.72504.AC
   PubMed Web of Science ®Google Scholar
• Roach RE, Cannegieter SC, Lijfering WM. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment. J Thromb Haemost. 2014;12(10):1593–1600. doi:10.1111/jth.12678
   PubMed Web of Science ®Google Scholar
• Martín-Martos F, Trujillo-Santos J, Barrón M, et al.; RIETE Investigators. Gender differences in cancer patients with acute venous thromboembolism. Thromb Res. 2015;135(Suppl 1):S12–5. doi:10.1016/S0049-3848(15)50433-7
   Web of Science ®Google Scholar
• McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368(9533):371–378. doi:10.1016/S0140-6736(06)69110-1
   PubMed Web of Science ®Google Scholar
• Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY. Anticoagulant-related gastrointestinal bleeding–could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med. 2014;46(8):672–678. doi:10.3109/07853890.2014.952327
   PubMed Web of Science ®Google Scholar
• Campello E, Spiezia L, Simion C, et al. Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Assoc. 2020;9(23):e018917. doi:10.1161/JAHA.120.018917
   PubMed Web of Science ®Google Scholar